The award recognizes Kirin Holdings' proprietary Lactococcus lactis strain Plasma (LC-Plasma) - the functional ingredient in iMUSE - for scientific research that supports its effects on the immune system, success in achieving health claims, as well as commercial growth.
Dr. Daisuke Fujiwara, General Manager, Health Science Department - who discovered LC-Plasma - accepted the award stating, "It's an honor for Kirin Holdings to be chosen for its Lactococcus lactis strain Plasma - the functional ingredient in iMUSE. This is the culmination of many years of research. Over 10 years ago, when I set out to do this research, my mission was to find ways to contribute to protection against viral infection. This award validates our hard work. Moving forward, Kirin Holdings will carry on this mission, finding more ways to contribute to the health of as many people as possible; first by making efforts to spread this kind of research through Asia."
To read more, visit KirinHoldings.com.